La Vecchia C, Levi F, Lucchini F, Garattini S
Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.
Anticancer Drugs. 1991 Jun;2(3):215-21. doi: 10.1097/00001813-199106000-00001.
Trends in mortality from four groups of cancers amenable to anti-cancer treatments (testicular cancer, Hodgkin's disease, leukemias and childhood cancers) between the late 1950s and the late 1980s were analyzed for the 23 larger European countries. In Western Europe, newer treatments led to the avoidance of approximately 1000 deaths from testicular cancer, 4000 from Hodgkin's disease, 4000 from leukemias, and 2500 from childhood cancers. In Eastern Europe, declines in mortality were observed only for childhood cancers, for a total of about 500 fewer deaths per year. Thus, approximately 11,000 deaths per year were avoided in Europe by newer cancer treatments, corresponding to 1% cancer deaths registered in the 23 larger European countries. A few thousand further deaths from these cancers could be avoided through more widespread and rational utilization of currently available therapies, particularly in Eastern Europe.
对23个欧洲大国在20世纪50年代末至80年代末期间,四类适合抗癌治疗的癌症(睾丸癌、霍奇金病、白血病和儿童癌症)的死亡率趋势进行了分析。在西欧,新的治疗方法避免了约1000例睾丸癌死亡、4000例霍奇金病死亡、4000例白血病死亡以及2500例儿童癌症死亡。在东欧,仅儿童癌症死亡率有所下降,每年总计减少约500例死亡。因此,欧洲通过新的癌症治疗方法每年避免了约11000例死亡,相当于23个欧洲大国登记的癌症死亡人数的1%。通过更广泛、合理地使用现有疗法,尤其是在东欧,可以避免数千例这些癌症的进一步死亡。